Abstract

BackgroundA prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method.MethodsWe collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier estimates in quartile groups of model predicted probabilities (MPP).ResultsThe AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respectively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test p < 0.0001). In the highest risk group, the HR were 6.04 [95% CI 2.70, 13.48] in the training set and 4.79 [2.310, 9.93] in the validation set.ConclusionsThe model for the prediction of 5-year DFS was successfully validated using the most stringent form of validation, in centers different from those involved in the development of the model. The external validation of the model confirms its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable.

Highlights

  • The sentinel lymph nodes (SLN) biopsy is consolidated as an effective procedure in the staging of solid tumors, especially in breast cancer [1,2,3]

  • The PLUTTO study [13] was developed as the logical step to collect evidence of the prognostic value of the total tumor load (TTL), defined as the sum of the copy number of Cytokeratin 19 (CK19) mRNA detected in every SLN examined, expressed as a concentration

  • Prognostic models were developed for disease-free survival (DFS), loco-regional DFS (LRDFS) and overall survival (OS), based on TTL, the patient’s age, and a risk score derived from tumor characteristics

Read more

Summary

Introduction

The sentinel lymph nodes (SLN) biopsy is consolidated as an effective procedure in the staging of solid tumors, especially in breast cancer [1,2,3]. This study concluded that the TTL allows to distinguish two groups of patients with different overall survival (OS) and disease-free survival (DFS), independently from other known prognostic factors, using a threshold of 25,000 copies/μL. From this evidence, prognostic models were developed for DFS, loco-regional DFS (LRDFS) and OS, based on TTL, the patient’s age, and a risk score derived from tumor characteristics. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method. The external validation of the model confirms its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call